Atossa Therapeutics, Inc. to Attend the 24th Annual H.C. Wainwright Global Investment Conference

SEATTLE, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious disease with a current focus on breast cancer and COVID-19, announced today that Kyle Guse, General Counsel & Chief Financial Officer will attend the 24th Annual H.C. Wainwright Global Investment Conference being held on September 12 14, 2022 at the Lotte New York Palace.

Metadata

Provider:

GlobeNewswire, Inc.

Retrieved on:

Wednesday, September 7, 2022

Information

Tags:

General counsel, Infection, COVID-19, Lotte New York Palace Hotel, Breast cancer, Therapy, GLOBE, ATOS, Conference, Nasdaq, Pharmaceutical industry

Geotags:

SEATTLE, WA, US

Organisation:

ATOSSA THERAPEUTICS, INC.

Summary

Key Points:

SEATTLE, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious disease with a current focus on breast cancer and COVID-19, announced today that Kyle Guse, General Counsel & Chief Financial Officer will attend the 24th Annual H.C. Wainwright Global Investment Conference being held on September 12 14, 2022 at the Lotte New York Palace.
Mr. Guse will be available for one-on-one meetings.
To request a meeting and to register for the conference, click below:
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19.

SEATTLE, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious disease with a current focus on breast cancer and COVID-19, announced today that Kyle Guse, General Counsel & Chief Financial Officer will attend the 24^th Annual H.C. Wainwright Global Investment Conference being held on September 12 – 14, 2022 at the Lotte New York Palace.

Mr. Guse will be available for one-on-one meetings. To request a meeting and to register for the conference, click below:

https://hcwevents.com/annualconference/

About Atossa Therapeutics

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19.

For more information, please visit www.atossatherapeutics.com

Contact:

Atossa Therapeutics, Inc.
Kyle Guse, General Counsel and Chief Financial Officer
[email protected]